Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.


Indirect systemic and direct oral factor Xa and direct oral factor IIa inhibitors with improved pharmacologic profiles compared with heparins and vitamin K antagonists are currently in clinical development. This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors… (More)
DOI: 10.1055/s-2008-1066023


10 Figures and Tables

Slides referencing similar topics